INCY vs MRNA
Incyte and Moderna, both Healthcare
Moderna is the larger company at $25B against $20B. Over the past year MRNA returned +93% against +65% for INCY. Ryufin's sector-relative Smart Score puts INCY ahead, 10/10 against 9/10.
| Figure | INCY | MRNA |
|---|---|---|
| Last close | $128 | $62.96 |
| Market cap | $20B | $25B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 18.1 | n/a |
| 1-year return | +65% | +93% |
| 5-year return | +66% | -81% |
| Ryufin Smart Scoresector-relative, 1–10 | 10/10 | 9/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Incyte
Revenue of $1.3B in Q1 2026, net income $303M. Its largest reported line is JAKAFI, 48% of the disclosed total.
Moderna
Revenue of $145M in Q2 2026, net income null. Its largest reported line is COVID19, 81% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.